Janssen Products LP drugs
5 results
Balversa (erdafitinib)
(Erdafitinib)Janssen Products LP
Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations, after disease progression on at least one prior systemic therapy. Use an FDA-approved companion diagnostic for patient selection. It's not recommended for those eligible for prior PD-1 or PD-L1 inhibitor therapy.
Intelence (etravirine)
(etravirine)Janssen Products LP
Usage: INTELENCE is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults and pediatric patients aged 2 years and older, in combination with other antiretroviral agents.
Prezcobix (darunavir ethanolate and cobicistat)
(DARUNAVIR ETHANOLATE and COBICISTAT)Janssen Products LP
Usage: PREZCOBIX is indicated for the treatment of HIV-1 in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients weighing at least 25 kg, provided there are no darunavir resistance-associated substitutions.
Prezista (darunavir)
(darunavir)Janssen Products LP
Usage: PREZISTA, in combination with ritonavir and other antiretroviral agents, is indicated for treating HIV-1 infection in adults and pediatric patients aged 3 and older.
Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide)
(Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide)Janssen Products LP
Usage: SYMTUZA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥40 kg) who have no prior antiretroviral treatment history or are virologically suppressed on a stable regimen for at least 6 months without known resistance mutations to darunavir or tenofovir.